Hims & Hers Shares Plunge After FDA Panel’s First ‘No’ on a Popular Peptide
Hims & Hers shares fell after FDA advisers approved six peptides for compounding but rejected the sleep-related peptide emideltide.
Andre's Feed↓
/ What's going on?
Filter:
FDA Approves Lytenava: First Official Eye-Only Version of Bevacizumab for Wet AMD
Purpose-built for the eye, it ends years of off-label repackaging.
Lilly’s Next Obesity Blockbuster Retatrutide on Track for 2027 Approval After Five Positive Phase 3 Studies
Analysts say Lilly’s retatrutide, heading for 2027 FDA filing after strong trials, could hit $3.8B sales by 2030 and help keep its edge over Novo Nordisk.
FDA Clears MannKind’s Furoscix ReadyFlow — Company Raises $50M to Cover Milestone Payment
Following FDA clearance of Furoscix ReadyFlow for heart failure and CKD edema, MannKind secures $50 million to fund the $45M milestone payment.
Zevra Therapeutics Shares Plunge After EU Rejects Arimoclomol for Rare Disease
Company plans to request re-examination.
Wise’s US Banking Ambitions Hit Roadblock as OCC Rejects Application
Wise shares drop after OCC rejects its US national trust bank application over compliance issues and policy changes. Firm plans new GENIUS Act bid.
Summit Therapeutics Warns of Cash Crunch That Could Threaten Operations Despite Strong Cancer Drug Progress
Summit Therapeutics says its cash won’t cover operations for a year, raising going-concern concerns. Shares fall as the company seeks funding while advancing ivonescimab development.
Tenet Healthcare Shares Surge After Strong Q2 Beat and Raised 2026 Outlook
Tenet beat expectations, raised forecasts, boosted profits and cash flow, and saw its stock jump sharply on strong hospital and outpatient performance.
AMD and Cerebras Partner on Ultra-Low-Latency AI Inference System
AMD and Cerebras team up to build faster AI systems that deliver quick answers while using less energy for real-time tasks.
FDA Panel Votes to Ease Access to Popular Peptide BPC-157
FDA advisers voted 8-6 to let compounding pharmacies make the popular peptide BPC-157 with a prescription. Not full approval.
Wedbush Adds Reddit to Best Ideas List With $250 Target Ahead of Q2 Earnings
Strong Q2 ads & AI deals expected. DA Davidson Buy at $200. Results July 30.
Scancell Acquires Neuphoria in All-Share Merger, Plans Nasdaq Listing Under SCLT
The merged company will list on Nasdaq as SCLT and raise up to $89M to fund Phase 3 of its melanoma immunotherapy iSCIB1+.
Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
Reddit Shares Plunge as It Considers Ending Google AI Partnership
Wells Fargo warns of revenue pressure but sees possible long-term upside for the platform.
AMD Invests Up to $5 Billion in Anthropic While Securing Huge GPU Contract
Anthropic secures up to 2GW of AMD Instinct MI450 GPUs and a $5B strategic investment from AMD. The deal strengthens AMD’s position in AI infrastructure against Nvidia while powering Claude’s growth.
Arrowhead’s Plozasiran Cuts Acute Pancreatitis Risk by Up to 100% in Phase 3 Severe Hypertriglyceridemia Trials
Arrowhead plans sNDA filing by end of 2026.
Repligen Acquires BioLife Solutions for $1.5 Billion to Strengthen Cell and Gene Therapy Leadership
Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.
Dyne Therapeutics Prices Upsized $375 Million Public Offering to Fuel Muscle Disease Pipeline
Dyne Therapeutics announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029.
Celldex Discontinues Barzolvolimab Development in Prurigo Nodularis After Phase 2 Failure
Celldex discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints.
PolyPid Secures $320 Million Partnership with Azurity for D-PLEX100 in U.S. and Canada
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
BMO Bullish on Trevi Therapeutics: Sees First-in-Class Potential for Haduvio in IPF Cough
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Crypto Markets Rally as CLARITY Act Nears Senate Floor Vote After White House Ethics Breakthrough
Bitcoin and Coinbase surge after Bessent signals the CLARITY Act is close to passage. White House ethics agreement removes final hurdle ahead of August recess.
Apple Partners with Klarna for New “Apple Upgrade” Device Leasing Program
The program covers most iPhones, Macs, iPads, and Apple Watches.
Jupiter Neurosciences Expands CNS Pipeline with ALA-002 Licensing Deal Worth Up to $100M
The deal adds a differentiated psychedelic asset to Jupiter’s CNS pipeline.
BTIG Calls Palvella’s 21% FDA-Driven Drop a Buying Opportunity
The FDA denied Breakthrough Therapy status for QTORIN. BTIG analysts view the decision as a short-term setback and maintain their Buy rating with a $215 price target.
Agios Ends Tebapivat Program in Sickle Cell Disease, Focuses on Mitapivat
Agios Pharmaceuticals announced it will not advance tebapivat in sickle cell disease after Phase 2 results failed to show a differentiated profile.
Novartis Beats Q2 2026 Expectations as New Drugs Offset Generic Pressure
Novartis reported strong Q2 2026 results with $14.41B sales and a core profit beat, driven by Kisqali (+43%) and Scemblix. Full-year guidance reaffirmed despite Entresto patent cliff.
Morgan Stanley Downgrades Tech Stocks as AI Payoff Doubts Mount
Morgan Stanley downgraded Salesforce, Workday, Intuit, SPS Commerce, Rapid7, PagerDuty, Wix, Vertex, and Nice, citing slow AI revenue growth and legacy business weakness. Price targets cut sharply.
Morgan Stanley Downgrades Adobe to Underweight, Slashes Price Target to $240 Amid AI and Execution Concerns
Morgan Stanley warns about the impact of generative AI, Adobe’s freemium strategy, and ongoing leadership transitions.
Karyopharm Shares Plunge After $3.7M Executive Cash Retention Program
RBC calls the drop overdone and sees it as a buying opportunity.
Akari Therapeutics Strengthens Balance Sheet and Prepares Phase 1 as Maxim Raises Rating to Buy
Backed by promising Trop2 ADC preclinical data, new financing, and strong ADC market momentum.
RBC Bullish on Nuvation Bio as Safusidenib Delivers Durable Responses in Glioma with New Phase 3 and Phase 2 Studies
Nuvation Bio reports strong long-term Phase 2 data for safusidenib (52% ORR, 79% PFS) and announces new Phase 3 and Phase 2 studies in IDH1-mutant glioma.
Armata Clears Key FDA Milestone, Prepares AP-SA02 Phase 3 Trial for 2026
Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.
Microsoft Deploys AMD Helios Racks in Azure, Boosting AMD’s Push Against Nvidia Dominance
Lower cost per token and strong TCO position AMD to gain AI market share from Nvidia.
Rhode Island’s Most Wanted Fugitive Lived as Biotech CMO — Arrested After 21 Years on the Run
Ronald Fischer, convicted of sexual assault, evaded justice for over two decades while living under the alias Richard Graydon as CMO of Immix Biopharma.
Maxim Initiates Buy Rating on Rein Therapeutics with $4 Price Target as LTI-03 Advances
Maxim highlights reduced risk and strong progress on LTI-03 for idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway with topline data expected by end of 2027.
Tempus AI Buys Personalis in $1.5B Deal to Advance Blood-Based Cancer Detection
The deal combines advanced cancer diagnostics with Tempus’ AI platform for improved surveillance.
Seaport Downgrades Birkenstock to Neutral on Weak Q2 Retail Demand
Seaport downgraded Birkenstock as weaker Q2 sales, fewer store orders, and economic pressures may hurt near-term growth.
Alibaba’s Qwen 3.8 Max Challenges AI Frontier as Chinese Models Surge
Alibaba’s new 2.4T-parameter Qwen 3.8 Max claims second place behind Anthropic’s Fable 5. Shares surged as China’s AI race intensifies with Moonshot’s Kimi K3.
Abivax Re-Engages Centerview as It Eyes Major Pharma Partnerships After $874M Raise
Abivax has resumed partnership talks with major pharma companies via Centerview Partners while preparing a potential independent U.S. launch of obefazimod.
Meta in Early Talks to Lease $10 Billion AI Compute Capacity to Anthropic
The move could create a new revenue stream for Meta while helping Anthropic reduce reliance on its existing SpaceX contract.
Seaport Downgrades Sonic Automotive to Neutral on Valuation Concerns
The firm remains constructive on the auto retail sector.
Zentalis Pharmaceuticals Gets Outperform Rating from Mizuho on Azenosertib Potential
Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
Kalaris Reinforces TH103’s Potential in Wet AMD Ahead of 2027 Catalyst
Kalaris reports 6-month follow-up data from 20 patients in TH103 Phase 1a trial. 29% of treatment-naïve patients remained injection-free for 6 months. Phase 1b/2 data expected H1 2027.
Intuitive Surgical Shares Plunge as Da Vinci Procedure Growth Slows Sharply
GLP-1 drugs and insurance uncertainty weigh on demand.
REGENXBIO Prices $100 Million Public Offering to Extend Cash Runway into 2028
Proceeds will support late-stage AAV gene therapy programs and extend cash runway to 2028.
GSK Discontinues Camlipixant After Mixed Phase 3 Results in Chronic Cough
The company will continue developing the drug for irritable bowel syndrome (IBS).
Stripe and Advent's $53B Bid for PayPal Deemed Inadequate by Board
The board has not yet formally responded to the proposal.
Jasper Bolsters Pipeline with Kira Acquisition and $132 Million Private Placement
Combined company advances KP-104 and briquilimab with cash runway through H2 2028.
Netflix Maintains 2026 Profitability Target While Narrowing Revenue Forecast
Netflix grows with higher sales and profits, but a weaker forecast worries investors and sends shares lower.
Google Delays Gemini 3.5 Pro Launch After Failing Key Benchmarks
The company is prioritizing quality and safety over speed amid rising competition from OpenAI and Anthropic.
Visa’s New Stablecoin Platform Challenges Circle as It Powers Open USD
Clear Street maintains Buy rating on V with $403 target amid rising competition with Circle’s USDC.
CareDx Shares Surge After Medicare Finalizes Transplant Testing Coverage
New policy brings clarity for kidney, heart, and lung patients.
Cash Constraints Force Wolfe to Downgrade Intellia to Underperform
Concerns over limited cash runway and slower clinical progress weigh on the stock.
Abbott Raises 2026 Outlook After Solid Q2 Beat Driven by Diagnostics and Devices
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.
UnitedHealth Shares Surge as Q2 Results Top Forecasts and Guidance Raised
Strong cost control and Optum performance drive recovery.
Eli Lilly Enters Psychedelic Mental Health Space with $3.8 Billion AtaiBeckley Acquisition
Eli Lilly secures BPL-003 and other novel psychedelic-inspired treatments designed to provide rapid, long-lasting relief for treatment-resistant depression.
Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Apple Intelligence Finally Gets Green Light in China, Boosting Upgrade Hopes
Powered by Alibaba’s Qwen model, the AI features — including upgraded Siri — are set to launch this fall with iOS 27 for Chinese users.
Novo’s Wegovy Pill Crushes Lilly’s Foundayo in Early Weight-Loss Battle
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.
Apple Rushes to Buy AI Chip Startups as Baltra Server Chip Faces Delays
As its M2 Ultra servers struggle and Baltra faces delays, Apple is actively acquiring semiconductor startups to build its own AI server infrastructure and cut dependence on third-party chips.
Veradermics Surges on Analyst Backing and Promising Oral Hair Loss Data in Women
90% of women reported improved hair coverage with no major safety issues.
Johnson & Johnson Q2 2026 Earnings: Beat and Raise, But Shares Slip on MedTech Miss
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
Elevance Health Reports Strong Q2 Beat but Shares Slide on Rising Medical Costs and Lower Margins
Despite beating Q2 estimates and lifting 2026 guidance, Elevance Health saw margins compress sharply. Core operating margin fell to 3.5% on higher medical costs.
JPMorgan Initiates Overweight on Tango Therapeutics with $46 Target as Pancreatic Cancer Data Impresses
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.
Stripe and Advent Launch $53 Billion Unsolicited Bid for PayPal
The unsolicited bid values the payments giant at a 28% premium.
Celcuity’s Revtorpyk Gets FDA Nod, Delivering Strong Results in PIK3CA Wild-Type Breast Cancer
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Spero Sells Portion of Utebzi Economics for $105M to Fuel SP001 Development
Spero Therapeutics monetizes its Utebzi royalty stream in a $105M non-dilutive financing deal with Healthcare Royalty, extending cash runway to 2H 2029 while funding SP001 development.
Claude for Teachers Pressures EdTech: Stride Stock Tumbles on AI Competition
The free AI platform for K-12 educators raises new competitive concerns for the online education provider.
Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
HCA Healthcare Cuts 2026 Earnings Guidance as Uninsured Patient Surge Weighs on Profits
$400M pre-tax hit in Q2 as ACA subsidies expire.
Avere Therapeutics Debuts on Nasdaq Backed by Ex-Akero Leaders Behind Novo Nordisk Acquisition
The company just went public via a $320M reverse merger with NextCure and is advancing a promising once-weekly oral IL-23 inhibitor for psoriasis and ulcerative colitis.
Apple Stock Downgraded by KeyBanc on Slowing iPhone Demand and Stretched Valuation
KeyBanc turns bearish on Apple, cutting the stock to Underweight and setting a $250 target. Analyst flags softening demand, iPhone headwinds, and rich valuation.
MBX Biosciences Appoints Steve Hoerter as Chairman and CEO, John Smither as CFO
The moves are aimed at supporting the company’s next phase of growth in precision peptide therapies.
Agenus Secures Up to $340M to Fund Pivotal Phase 3 ROBBIN Trial in Neoadjuvant Colon Cancer
H.C. Wainwright boosts Agenus’ price target to $30 from $23, reiterating a Buy rating.
FDA Approves First At-Home Starting Dose for Leqembi Alzheimer’s Treatment
RBC keeps Outperform at $242, Truist upgrades to Buy ($235 target).
Strong Medicare Outlook Drives Wells Fargo’s Bullish Upgrade on Humana
Analyst highlights improving Medicare margins and star ratings for stronger 2028 earnings.
Oncolytics Biotech Advances REO 033 Trial with Promising Pelareorep Data in Hard-to-Treat Colorectal Cancer
New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026.
Enlivex Secures FDA RMAT Designation for Allocetra in Knee Osteoarthritis
Phase IIb trial now underway with first U.S. patient dosed.
TNXP Stock Rises on Expanded Medicare Access for Fibromyalgia Drug TONMYA
Tonix secured expanded Medicare coverage for its fibromyalgia drug TONMYA, reaching approximately 9 million additional patients starting January 2027.
Bempikibart Delivers Promising Hair Regrowth in Alopecia Trial, Sending Q32 Bio Stock Soaring
The experimental treatment showed meaningful hair regrowth and a favorable safety profile.
Goldman Sachs Initiates Coverage on Stoke Therapeutics with Buy Rating and $44 Price Target
The firm sees strong potential for zorevunersen in treating Dravet syndrome.
First New Essential Tremor Therapy in 50+ Years: Goldman Bullish on Praxis Precision
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
Analyst Upgrade Boosts BeOne Medicines as Brukinsa Outlook Strengthens
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
CONMED Weighs Strategic Sale as Takeover Interest Emerges
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.
Letterboxd in Talks for $250 Million Sale as Netflix, Sony, and Paramount Circle the Film Platform
Concerns grow over the platform’s independence as it hits 30 million users.
BofA Sees Meta’s AI Chip Breakthrough as Major Turning Point for Cost Control
Bank of America calls Meta’s custom AI chip progress and faster, cheaper 14GW infrastructure buildout a “big positive.” Iris production starts September 2026.
Tencent Set to Become Largest Shareholder of AI Startup Manus After Unwinding Meta’s $2B Deal
Tencent teams up with early investors to buy back AI startup Manus from Meta at $2B valuation.
Circle Secures Final OCC Approval to Launch First National Digital Currency Bank
The milestone boosts USDC credibility and institutional adoption.
SK Hynix Makes Historic $26.5 Billion Nasdaq Debut, Largest Foreign U.S. Listing Ever
Oversubscribed 7x amid surging AI demand for HBM chips.
Netflix’s Engagement Crisis: Profits Soar, But Viewers Are Tuning Out
The streaming giant is fighting back with live channels, ad-tier growth, and potential sports rights.
Bausch + Lomb Discontinues BL1107 Eye Drops for Glaucoma After Phase 2 Miss
The company will discontinue the topical program but continue advancing a sustained-release implant for geographic atrophy.
Steel Partners Launches $16.75 Takeover Bid for InMode, Surpassing CEO-Backed Offer
The firm criticizes CEO Moshe Mizrahy and urges the board to act.
FDA Clears Fate Therapeutics’ Dual-Target CAR-T FT839 for Autoimmune Diseases
Following positive FT819 data in systemic sclerosis, the company now targets multiple autoimmune indications.
Oppenheimer Initiates Outperform Coverage on Connect Biopharma with $8 Target, Implies 3.6x Upside
Rademikibart’s rapid action in acute asthma & COPD positions it for major upside ahead of Phase 2 readouts.
Qiagen Draws Early Takeover Interest from EQT, Advent, and KKR
No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation.
Micron to Invest $250 Billion in U.S. by 2035, Targeting 40% Domestic DRAM Production
The company poured the first concrete at its Clay, New York site, marking the start of the largest semiconductor project in U.S. history.
Starbucks Builds In-House AI Tools to Cut Reliance on Microsoft, IBM, and Oracle
Starbucks aims to slash $400M in annual software spend by building its own AI tools, challenging Microsoft Dynamics, IBM TRIRIGA, and Oracle Simphony.
Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach
With key MAD data for DM1 and FSHD siRNA programs expected in H2 2026, SRPT stock shows strong growth potential.